MC4R agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
== Commercial syntheses of amino acids == The commercial production of amino acids usually relies on mutant bacteria that overproduce individual amino acids using glucose as a carbon source. Some amino acids are produced by enzymatic conversions of synthetic intermediates. 2-Aminothiazoline-4-carboxylic acid is an intermediate in the industrial synthesis of L-cysteine for example. Aspartic acid is produced by the addition of ammonia to fumarate using a lyase.
Observe the value of the friction factor for laminar flow at a Reynolds number of 1000. If the value of the friction factor is 0.064, then the Darcy friction factor is plotted in the Moody diagram. Note that the nonzero digits in 0.064 are the numerator in the formula for the laminar Darcy friction factor: fD = 64/Re. If the value of the friction factor is 0.016, then the Fanning friction factor is plotted in the Moody diagram. Note that the nonzero digits in 0.016 are the numerator in the formula for the laminar Fanning friction factor: f = 16/Re. The procedure above is similar for any available Reynolds number that is an integer power of ten. It is not necessary to remember the value 1000 for this procedure—only that an integer power of ten is of interest for this purpose.
=== Health care === Albany is served by Samaritan Albany General Hospital, a 76-bed medical facility that is the main hospital for the city and has been in operation since 1924. Albany is also served by Samaritan North Albany Urgent Care and Geary Street Urgent Care, both of which are part of Samaritan Health Services. The unaffiliated Albany Family & Specialty Medicine also provides medical services to the community.
4-HO-MET, also known as 4-hydroxy-N-methyl-N-ethyltryptamine, as well as metocin or methylcybin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It is a close structural analogue of psilocin (4-HO-DMT) and is the 4-hydroxyl analogue of methylethyltryptamine (MET). 4-HO-MET was discovered by Alexander Shulgin in the 1970s. It was first described in the literature by David Repke and colleagues in 1981. The drug was encountered as a novel recreational and designer drug by 2008. It is openly sold as a legal recreational drug in the United States.
Rosemary Pauline West (née Letts; born 29 November 1953) is an English serial killer, serial rapist and child molester who collaborated with her husband, Fred West, in the torture and murder of at least ten young women between 1973 and 1987; she also murdered Fred's eight-year-old stepdaughter, Charmaine, in 1971. The majority of these murders took place at the West residence at 25 Cromwell Street in Gloucester. Rose West is currently an inmate at New Hall Prison in Flockton, West Yorkshire, after being convicted in 1995 and sentenced to ten life terms with a whole life order. Fred West died by suicide in prison that same year while awaiting trial, following the couple's arrest in 1994.
Sources: en.wikipedia.org
== Legal disposal and reuse of waste oil == Legitimate producers of gutter oil sell the processed oil for use in the chemical or energy industries. However, such refiners can also have illegal side business, as the prices attained by selling it as cooking oil are much higher than if it is sold to the chemical or energy industries such as KBR Energy. Yellow and brown grease typical of gutter oil are acceptable raw feedstocks for products not intended for human consumption, such as plastics, rubber, rooftops, soap, cosmetics, and bio-fuel. In the city of Shanghai, it was reported that over 2,000 buses ran on biodiesel that was made from gutter oil, and many gas stations in Shanghai offered gasoline that was produced in part from gutter oil. Sustainable utilization of gutter oil for biofuel production is being explored using different chemical and enzymatic methods.
== History == In 1998, MuscleTech launched Cell-Tech, a creatine-carbohydrate-alpha lipoic acid supplement. In September 2018, Muscletech is partnering up to Rob Gronkowski to create a high-protein candy bar. In October 2018, MuscleTech partnered with Homes For Our Troops. In April 2019, MuscleTech had partnered up with Tough Mudder. In July 2019, MuscleTech launched the Prime Series, a private label sports nutrition line exclusive to Amazon. In April 2021, MuscleTech is announced the addition of a new general manager. MuscleTech, through its parent company Iovate Health Sciences, is a partner of the Metabolism & Sports Science Lab at the University of Toronto. In February 2022, MuscleTech announced they are looking for their next Brand Superstar. In April 2024, Muscletech and Trust Group came to an agreement for Trust Group to manufacture and market MuscleTech products in the Brazilian market.
In AMS v Union locale des syndicats CGT a French trade union claimed that the French Labour Code should not exclude casual workers from counting toward the right to set up a work council that an employing entity must inform and consult. They said this contravened the Information and Consultation of Employees Directive and also CFREU article 27. The Court of Justice agreed that the French Labour Code was incompatible with the Directive, but held that article 27 was expressed too generally to create direct rights. On this view, legislation was necessary to make abstract human rights principles concrete, and legally enforceable. Beyond human rights, the Court of Justice has recognised at least five further 'general principles' of EU law. The categories of general principles are not closed, and may develop according to the social expectations of people living in Europe.
by sending weapons to one of the sides) between Russia and Ukraine to negotiate an end to the conflict and invited the US to join Brazil in a new global climate governance On 28 February, Brazilian Environment minister Marina Silva met with John Kerry, the White House envoy for climate change during his visit to Brazil, and announced the resumption of a US-Brazil environment group created in 2015 to debate energy transition, low carbon economy, climate change mitigation, indigenous peoples protection and bioconomy among others between the two countries. Nevertheless, no contribution to the Amazon Fund was announced by Kerry during the visit. In September 2023, Lula and Biden met on the sidelines of the 78th United National General Assembly (UNGA), in New York, to launch an initiative to promote worker's rights. In June 2024, it was reported that Brazil and the US were preparing to launch a joint green transition partnership involving lithium, niobium and other strategic minerals to expand and develop both countries' supply chains.
=== Autoimmune conditions === The two main autoimmune conditions that impact the muscular system are myositis (including polymyositis and dermatomyositis), and myasthenia gravis. Hypotonia Loss of muscular tone or a diminished resistance to passive stretching. Myositis Inflammation of muscles Rhabdomyolysis Breakdown of skeletal muscle with release of intracellular contents
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.